February 15, 2011, Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic Test - Test to Identify FLT3 Positive AML Patients Invivoscribe Technologies, Inc., a world leader in personalized molecular medicine, announced today that they have entered into a collaboration agreement with Novartis to develop and commercialize a companion diagnostic test. The test aims to identify FLT3 positive acute myeloid leukemia (AML) patients for specific use in connection with the Novartis development compound, midostaurin (PKC412).
April 19, 2010, Launch of Ceplene for AML Remission Maintenance Available in EU
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced today, that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 – in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.
April 19, 2010, Bringing leukemia out of hiding
April 14, 2010, 'Vicious circle' that promotes leukemia found
The Times of India
April 6, 2010, DNA Drug Promising in Older Leukemia Patients
April 7, 2010, CytRx to Initiate a Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer
Bafetinib is a potent, orally available, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor, which is currently being planned as a third-line treatment for patients with chronic myeloid leukemia (CML) or certain forms of acute myeloid leukemia (AML) that are refractory or intolerant of other approved treatments. In November 2008, CytRx announced that bafetinib demonstrated clinical responses in patients with CML in an international Phase I dose-ranging clinical trial conducted in patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to Gleevec and, in some cases, second-line tyrosine kinase inhibitors such as dasatinib and nilotinib. Bafetinib has been granted Orphan Drug Status for the treatment of Philadelphia chromosome-positive (Ph+) CML by the FDA.
April 2, 2010, Mylotarg® Effective for Older Intermediate-risk AML Patients